We are excited to announce the launch of a new recombinant Glial Fibrillary Acidic Protein (GFAP) antigen, Cat# 8G47, which is suitable for use as a standard or calibrator in immunoassays. In recent years, GFAP has emerged as an important fluid biomarker, aiding in the diagnosis and monitoring of neurological conditions. Compared to the cerebrospinal fluid (CSF) test, the blood GFAP test provides an even more convenient, non-invasive assessment method. GFAP is an intermediate filament protein found in astrocytes within the central nervous system (CNS). When the brain or spinal cord suffers injury, such as from trauma or stroke, GFAP is released into the bloodstream. It is a sensitive marker for diagnosing traumatic brain injury (TBI), particularly in detecting mild TBI. GFAP combined with other related biomarkers are considered game changers by researchers and clinicians, aiding in the early and accurate diagnosis of mild TBI and enabling prompt treatment. 

GFAP is not only an indicator of brain and spinal cord injury; elevated levels have also been associated with neurodegenerative conditions such as Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). Both GFAP and neurofilament light (NfL) are potential blood-based biomarkers indicative of ongoing inflammatory and neurodegenerative processes. In addition to these, Hytest also offers a comprehensive neuroscience biomarker portfolio. For more information about these biomarkers, please check our neuroscience brochure.  

Hytest aims to provide its customers with a recombinant GFAP antigen that is highly suitable for developing reliable and accurate diagnostic assays, while ensuring scalability and cost-effectiveness. We also guarantee purity and lot-to-lot consistency of our recombinant antigen, 8G47, and have demonstrated its immunochemical stability using our in-house GFAP83cc-GFAP81cc prototype assay (Cat# 4G25). For more information, please refer to our Data Sheet and TechNotes.